Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses

• Published in: Respiratory research Vol. 24; no. 1; p. 305
• Main Authors: Akenroye, Ayobami, Nopsopon, Tanawin, Cho, Laura, Moll, Matthew, Weiss, Scott T
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.12.2023; BioMed Central; BMC
• Subjects: Adult; Analysis; Anti-Asthmatic Agents; Aptamers; Asthma; Asthma - chemically induced; Asthma - diagnosis; Asthma - drug therapy; Biobanks; Biological products; Biomarkers; Body mass index; Body size; CD9 antigen; Diagnosis; Dosage and administration; Drug therapy; Female; Humans; Immunoglobulin E; Leukocytes (eosinophilic); Male; MAP kinase; Mepolizumab; Monoclonal antibodies; Mucin-1; Mucins; Myostatin; Myostatin - therapeutic use; Network medicine; NF-κB protein; Omalizumab; Omalizumab - adverse effects; Omalizumab - therapeutic use; Patient outcomes; Patients; Plasma; Protein-protein interactions; Proteins; Protein–protein interaction; Proteomics; Reagents; Therapy; United States; Cytokines; Network medicine; Systems biology; Proteomics; Monoclonal antibodies; Omalizumab; Mepolizumab; Protein–protein interaction; Asthma
• ISSN: 1465-993X; 1465-9921; 1465-993X; 1465-9921
• DOI: 10.1186/s12931-023-02620-1

Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab. Aptamer-based proteomic profiling (SomaScan) was used to assess 1437 proteins from 51 patients with moderate to severe asthma who received omalizumab (n = 29) or mepolizumab (n = 22). Response was defined as the change in asthma-related exacerbations in the 12 months following therapy initiation. All models were adjusted for age, sex, and pre-treatment exacerbation rate. Additionally, body mass index was included in the omalizumab model and eosinophil count in the mepolizumab model. We evaluated the association between molecular signatures and response using negative binomial regression correcting for the false discovery rate (FDR) and gene set enrichment analyses (GSEA) to identify associated pathways. Over two-thirds of patients were female. The average age for omalizumab patients was 42 years and 57 years for mepolizumab. At baseline, the average exacerbation rate was 1.5/year for omalizumab and 2.4/year for mepolizumab. Lower levels of LOXL2 (unadjusted p: 1.93 × 10E-05, FDR-corrected: 0.028) and myostatin (unadjusted: 3.87 × 10E-05, FDR-corrected: 0.028) were associated with better response to mepolizumab. Higher levels of CD9 antigen (unadjusted: 5.30 × 10E-07, FDR-corrected: 0.0006) and MUC1 (unadjusted: 1.15 × 10E-06, FDR-corrected: 0.0006) were associated with better response to omalizumab, and LTB4R (unadjusted: 1.12 × 10E-06, FDR-corrected: 0.0006) with worse response. Protein-protein interaction network modeling showed an enrichment of the TNF- and NF-kB signaling pathways for patients treated with mepolizumab and multiple pathways involving MAPK, including the FcER1 pathway, for patients treated with omalizumab. This study provides novel fundamental data on proteins associated with response to mepolizumab or omalizumab in severe asthma and warrants further validation as potential biomarkers for therapy selection.